ESMO Breast 2024 | Exploring treatment resistance markers in metastatic lobular breast cancer

Jason Mouabbi, MD, The University of Texas MD Anderson Cancer Center, Houston, TX, discusses emerging data on treatment resistance markers in metastatic lobular carcinoma and the role of targeted therapies and immunotherapies. Studies show promising responses to immunotherapy in lobular histology, with specific pathways like PI3K/AKT/mTOR being key targets. This interview took place at the 2024 European Society for Medical Oncology (ESMO) Breast Cancer Annual Congress in Berlin, Germany.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.